Medical technology company HR HealthCare announced on Thursday the establishment of the HR HealthCare Foundation.
The Foundation provides a dedicated framework for supporting individuals, healthcare initiatives, and local communities, and expanding that support over time. Established as a separate charitable organisation, it extends HR HealthCare's aim to positively impact people's lives beyond the products and services it provides.
The HR HealthCare Foundation is intended to focus on three areas: Dreams, creating meaningful experiences for individuals living with life-altering health conditions and disabilities; Healthcare Initiatives, supporting nonprofit organisations and healthcare programmes that advance research, innovation, and patient-centred care in areas aligned with HR HealthCare's focus; and Community Initiatives, supporting local charitable organisations and community programmes that provide services, assistance, and outreach to individuals and families in need.
Ascletis reports positive US Phase II topline results for ASC30 in diabetes
MetaVia announces presentation of DA-1726 Phase 1 data at Precision Liver Symposium
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
United Therapeutics receives FDA clearance to advance inhaled PAH therapy into clinical trials
DifGen Pharmaceuticals completes European Decentralised Procedure for Tafamidis 61 mg Capsules
Astellas and Audax Biosciences sign exclusive option and licence agreement for DAX-044
IRLAB Therapeutics receives US patent allowance for Parkinson's drug candidate IRL1117
Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult
Enhertu wins EU approval for HER2-positive early breast cancer treatment
Riboscience reports Phase 1a/b overall survival data for ENPP1 inhibitor RBS2418
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
Innovent Biologics' sintilimab new indication application accepted for review by NMPA
Genmab reports 28.2-month median overall survival with petosemtamab combination in Phase 2 trial